Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ESMO Congress 2026 · Barcelona, Spain
200 shown of 2,309 total abstracts
  1. Abstract 10482026-09-04 · 20:15 CT · Hall B1
    Real-world effectiveness of Kisqali vs standard of care in HR+ breast cancer
    M. Krop, M.C. Garassino, C. Saura, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  2. Abstract 17232026-09-03 · 15:30 CT · Hall B1
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-186 study)
    S. Antonia, C. Saura, A. Spira · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  3. Abstract 11122026-09-03 · 21:15 CT · S406
    Long-term follow-up of Lynparza maintenance for HR+ breast cancer: OlympiA-842
    S. Antonia, T. Mok, P. Schmid, et al. · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  4. Abstract 19562026-09-02 · 19:30 CT · S406
    Keytruda plus chemotherapy in previously untreated TNBC: updated analysis from KEYNOTE-910
    H. Borghaei, A. Spira, G. Curigliano, et al. · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  5. Abstract 10442026-09-01 · 20:30 CT · E450
    MONARCH-225: Verzenio (abemaciclib) maintenance in HR+ breast cancer
    L. Paz-Ares, S. Tolaney, T. Mok, et al. · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  6. Abstract 19772026-09-03 · 20:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-371 study)
    H. Rugo, F. Andre, E. Winer, et al. · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  7. Abstract 16582026-09-02 · 14:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-764 study)
    M.C. Garassino, R. Herbst · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  8. Abstract 18282026-09-05 · 15:45 CT · Hall B1
    Real-world effectiveness of Verzenio vs standard of care in HR+ breast cancer
    H. Borghaei, T. Mok, M. Krop, et al. · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  9. Abstract 16512026-09-03 · 16:45 CT · S406
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-540 study)
    L. Paz-Ares, C. Robert, S. Modi, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  10. Abstract 16312026-09-03 · 16:45 CT · S406
    Long-term follow-up of Kisqali 3L+ for HR+ breast cancer: MONALEESA-824
    H. Borghaei, G. Curigliano, L. Paz-Ares, et al. · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  11. Abstract 13462026-09-04 · 16:45 CT · S100A
    Long-term follow-up of Ibrance adjuvant for HR+ breast cancer: PALOMA-336
    L. Paz-Ares, C. Robert, J. Cortes, et al. · Stanford Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  12. Abstract 11752026-09-05 · 14:00 CT · S406
    Long-term follow-up of Trodelvy maintenance for TNBC: ASCENT-74
    F. Andre, H. Rugo, C. Robert, et al. · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  13. Abstract 13792026-09-05 · 15:15 CT · S100A
    Quality of life outcomes with Enhertu in patients with HR+ breast cancer
    S. Antonia, L. Paz-Ares · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  14. Abstract 12932026-09-05 · 21:30 CT · S406
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-748
    F. Andre, S. Tolaney, L. Paz-Ares, et al. · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  15. Abstract 17472026-09-01 · 16:30 CT · S100A
    Real-world effectiveness of Enhertu vs standard of care in HR+ breast cancer
    M. Reck, S. Antonia, P. Schmid, et al. · Princess Margaret Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  16. Abstract 15872026-09-01 · 14:45 CT · Arie Crown Theater
    Long-term follow-up of Trodelvy 1L for TNBC: ASCENT-635
    R. Herbst, M. Krop, F. Andre, et al. · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  17. Abstract 16142026-09-05 · 20:00 CT · S406
    MONALEESA-169: Kisqali (ribociclib) maintenance in HR+ breast cancer
    M. Reck, L. Paz-Ares · Princess Margaret Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  18. Abstract 14122026-09-02 · 13:45 CT · S406
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-894 study)
    J. Brahmer, H. Rugo, S. Tolaney · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  19. Abstract 19862026-09-03 · 19:45 CT · S406
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-133 study)
    G. Curigliano, M.C. Garassino, E. Winer · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  20. Abstract 12742026-09-02 · 21:45 CT · S406
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-633 study)
    R. Herbst, L. Paz-Ares, J. Cortes, et al. · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  21. Abstract 12772026-09-03 · 21:30 CT · Arie Crown Theater
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-507
    S. Modi, C. Saura, M. Krop · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  22. Abstract 14732026-09-03 · 18:45 CT · S100A
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-4 study)
    S. Peters, S. Antonia, M. Reck · Princess Margaret Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  23. Abstract 14912026-09-01 · 13:30 CT · S406
    Quality of life outcomes with Verzenio in patients with HR+ breast cancer
    T. Mok, S. Tolaney, R. Herbst, et al. · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  24. Abstract 17992026-09-01 · 16:00 CT · Hall B1
    Quality of life outcomes with Keytruda in patients with TNBC
    H. Borghaei, J. Brahmer, G. Curigliano, et al. · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  25. Abstract 19852026-09-02 · 13:30 CT · E450
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-184 study)
    M. Reck, N. Rizvi · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  26. Abstract 10602026-09-05 · 20:15 CT · S406
    MONARCH-848: Verzenio (abemaciclib) 1L in HR+ breast cancer
    T. Mok, R. Herbst · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  27. Abstract 17352026-09-04 · 13:00 CT · Hall B1
    PALOMA-307: Ibrance (palbociclib) adjuvant in HR+ breast cancer
    C. Robert, C. Saura, M. Krop, et al. · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  28. Abstract 19082026-09-02 · 15:45 CT · S100A
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-686 study)
    S. Peters, R. Herbst, H. Rugo, et al. · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  29. Abstract 12202026-09-04 · 18:00 CT · S406
    Quality of life outcomes with Kisqali in patients with HR+ breast cancer
    M. Reck, S. Modi, R. Herbst, et al. · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  30. Abstract 12592026-09-04 · 21:30 CT · S406
    Long-term follow-up of Verzenio maintenance for HR+ breast cancer: MONARCH-825
    G. Curigliano, J. Brahmer · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  31. Abstract 15622026-09-01 · 21:30 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-634
    C. Saura, H. Rugo, M.C. Garassino · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  32. Abstract 13892026-09-05 · 15:00 CT · E450
    Quality of life outcomes with Trodelvy in patients with TNBC
    H. Borghaei, G. Curigliano, J. Cortes · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  33. Abstract 17852026-09-04 · 20:45 CT · S100A
    PALOMA-386: Ibrance (palbociclib) 1L in HR+ breast cancer
    J. Cortes, S. Modi, S. Antonia · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  34. Abstract 15562026-09-03 · 18:45 CT · S100A
    Real-world effectiveness of Trodelvy vs standard of care in TNBC
    G. Curigliano, M.C. Garassino, L. Paz-Ares · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  35. Abstract 19152026-09-03 · 21:00 CT · Arie Crown Theater
    OlympiA-110: Lynparza (olaparib) 3L+ in HR+ breast cancer
    A. Spira, H. Rugo, E. Winer, et al. · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  36. Abstract 19112026-09-05 · 20:15 CT · S100A
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-484
    H. Borghaei, R. Herbst, F. Andre, et al. · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  37. Abstract 10682026-09-03 · 15:30 CT · Arie Crown Theater
    Keytruda plus chemotherapy in previously untreated TNBC: updated analysis from KEYNOTE-289
    H. Borghaei, S. Peters, R. Herbst, et al. · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  38. Abstract 11642026-09-01 · 18:30 CT · E450
    MONALEESA-242: Kisqali (ribociclib) 2L in HR+ breast cancer
    C. Robert, E. Winer, R. Herbst, et al. · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  39. Abstract 11182026-09-03 · 15:30 CT · Hall B1
    ASCENT-548: Trodelvy (sacituzumab govitecan) neoadjuvant in TNBC
    R. Herbst, L. Paz-Ares · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  40. Abstract 13482026-09-02 · 18:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-932 study)
    P. Schmid, M. Krop, E. Winer, et al. · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  41. Abstract 11502026-09-01 · 20:45 CT · Arie Crown Theater
    Long-term follow-up of Lynparza adjuvant for HR+ breast cancer: OlympiA-285
    J. Brahmer, M.C. Garassino · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  42. Abstract 16222026-09-03 · 13:30 CT · E450
    Long-term follow-up of Ibrance maintenance for HR+ breast cancer: PALOMA-99
    J. Cortes, G. Curigliano · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  43. Abstract 12952026-09-03 · 21:00 CT · Hall B1
    Keytruda plus chemotherapy in previously untreated TNBC: updated analysis from KEYNOTE-64
    A. Spira, C. Saura, R. Herbst, et al. · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  44. Abstract 18112026-09-04 · 15:45 CT · S406
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-222 study)
    M.C. Garassino, M. Krop, F. Andre · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  45. Abstract 17112026-09-02 · 18:15 CT · E450
    PALOMA-568: Ibrance (palbociclib) neoadjuvant in HR+ breast cancer
    J. Cortes, H. Borghaei, H. Rugo · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  46. Abstract 14992026-09-04 · 15:15 CT · S406
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-743
    J. Cortes, P. Schmid, G. Curigliano · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  47. Abstract 17912026-09-05 · 15:45 CT · Hall B1
    MONARCH-639: Verzenio (abemaciclib) neoadjuvant in HR+ breast cancer
    A. Spira, N. Rizvi · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  48. Abstract 11832026-09-02 · 21:00 CT · Arie Crown Theater
    MONARCH-507: Verzenio (abemaciclib) 3L+ in HR+ breast cancer
    C. Robert, E. Winer, C. Saura, et al. · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  49. Abstract 16182026-09-04 · 18:30 CT · S100A
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-602 study)
    R. Herbst, T. Mok · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  50. Abstract 18402026-09-04 · 20:45 CT · S406
    Long-term follow-up of Tecentriq maintenance for TNBC: IMpower-865
    M. Krop, J. Brahmer, F. Andre · Princess Margaret Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  51. Abstract 19062026-09-04 · 21:15 CT · E450
    ASCENT-523: Trodelvy (sacituzumab govitecan) 1L in TNBC
    L. Paz-Ares, P. Schmid, A. Spira · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  52. Abstract 17372026-09-01 · 14:00 CT · Hall B1
    Quality of life outcomes with Ibrance in patients with HR+ breast cancer
    T. Mok, H. Borghaei, S. Antonia, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  53. Abstract 17822026-09-02 · 15:30 CT · E450
    Quality of life outcomes with Lynparza in patients with HR+ breast cancer
    J. Cortes, H. Borghaei, T. Mok, et al. · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  54. Abstract 17362026-09-03 · 14:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-973 study)
    M. Reck, S. Tolaney · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  55. Abstract 13812026-09-04 · 16:00 CT · Hall B1
    MONALEESA-14: Kisqali (ribociclib) neoadjuvant in HR+ breast cancer
    M.C. Garassino, J. Cortes, S. Modi, et al. · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  56. Abstract 17562026-09-03 · 13:30 CT · Arie Crown Theater
    Long-term follow-up of Kisqali adjuvant for HR+ breast cancer: MONALEESA-399
    H. Borghaei, R. Herbst · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  57. Abstract 18052026-09-04 · 18:30 CT · S406
    MONARCH-604: Verzenio (abemaciclib) 1L in HR+ breast cancer
    M. Krop, H. Borghaei, J. Brahmer, et al. · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  58. Abstract 19922026-09-05 · 16:45 CT · S100A
    MONARCH-963: Verzenio (abemaciclib) neoadjuvant in HR+ breast cancer
    H. Rugo, S. Modi, M. Reck, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  59. Abstract 16862026-09-05 · 20:00 CT · Arie Crown Theater
    MONARCH-562: Verzenio (abemaciclib) maintenance in HR+ breast cancer
    R. Herbst, C. Robert · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  60. Abstract 18502026-09-04 · 20:45 CT · Hall B1
    OlympiA-319: Lynparza (olaparib) 3L+ in HR+ breast cancer
    G. Curigliano, M. Reck, M. Krop, et al. · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  61. Abstract 10862026-09-03 · 15:45 CT · Hall B1
    Real-world effectiveness of Ibrance vs standard of care in HR+ breast cancer
    M.C. Garassino, A. Spira, H. Borghaei · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  62. Abstract 15642026-09-03 · 21:00 CT · Hall B1
    IMpower-67: Tecentriq (atezolizumab) adjuvant in TNBC
    C. Robert, M.C. Garassino, L. Paz-Ares, et al. · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  63. Abstract 15562026-09-01 · 14:15 CT · Hall B1
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-352 study)
    S. Tolaney, P. Schmid, R. Herbst, et al. · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  64. Abstract 16952026-09-05 · 19:15 CT · Arie Crown Theater
    Long-term follow-up of Kisqali 3L+ for HR+ breast cancer: MONALEESA-595
    H. Rugo, S. Antonia, M. Reck · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  65. Abstract 12922026-09-03 · 21:15 CT · S100A
    Long-term follow-up of Trodelvy 1L for TNBC: ASCENT-170
    S. Tolaney, A. Spira · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  66. Abstract 13492026-09-02 · 18:15 CT · Hall B1
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-218 study)
    C. Robert, M. Krop, G. Curigliano, et al. · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  67. Abstract 18912026-09-05 · 15:00 CT · Hall B1
    MONALEESA-936: Kisqali (ribociclib) 2L in HR+ breast cancer
    P. Schmid, R. Herbst, S. Antonia · Stanford Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  68. Abstract 13682026-09-02 · 20:45 CT · Hall B1
    Biomarker subgroup analysis of Keytruda in TNBC (the KEYNOTE-175 study)
    C. Robert, S. Modi, H. Rugo · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  69. Abstract 15242026-09-03 · 15:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-826 study)
    C. Saura, M. Reck · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  70. Abstract 11482026-09-03 · 18:45 CT · S406
    MONARCH-277: Verzenio (abemaciclib) 2L in HR+ breast cancer
    M. Krop, G. Curigliano, H. Rugo, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  71. Abstract 18722026-09-05 · 21:30 CT · S406
    Long-term follow-up of Trodelvy maintenance for TNBC: ASCENT-99
    E. Winer, R. Herbst, M. Krop · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  72. Abstract 16922026-09-04 · 15:15 CT · Arie Crown Theater
    Long-term follow-up of Verzenio adjuvant for HR+ breast cancer: MONARCH-962
    S. Antonia, S. Modi, C. Robert, et al. · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  73. Abstract 12652026-09-01 · 21:15 CT · S406
    Long-term follow-up of Kisqali 1L for HR+ breast cancer: MONALEESA-528
    J. Cortes, M.C. Garassino, M. Krop, et al. · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  74. Abstract 12272026-09-05 · 20:00 CT · S406
    IMpower-831: Tecentriq (atezolizumab) 3L+ in TNBC
    S. Peters, M. Krop, C. Saura, et al. · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  75. Abstract 11332026-09-04 · 16:00 CT · E450
    Real-world effectiveness of Tecentriq vs standard of care in TNBC
    S. Antonia, A. Spira · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  76. Abstract 14452026-09-05 · 19:00 CT · E450
    Quality of life outcomes with Tecentriq in patients with TNBC
    C. Robert, T. Mok, M. Reck, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  77. Abstract 18392026-09-05 · 14:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-914 study)
    A. Spira, R. Herbst · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  78. Abstract 19762026-09-02 · 14:15 CT · Arie Crown Theater
    Long-term follow-up of Kisqali neoadjuvant for HR+ breast cancer: MONALEESA-305
    M.C. Garassino, S. Peters, J. Cortes · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  79. Abstract 10522026-09-04 · 15:15 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-484
    H. Rugo, H. Borghaei, S. Modi, et al. · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  80. Abstract 11572026-09-05 · 18:00 CT · S406
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-565
    N. Rizvi, G. Curigliano, J. Brahmer, et al. · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  81. Abstract 10532026-09-02 · 20:00 CT · Arie Crown Theater
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-512
    N. Rizvi, M. Reck, A. Spira, et al. · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  82. Abstract 17792026-09-03 · 13:45 CT · Hall B1
    Long-term follow-up of Verzenio 1L for HR+ breast cancer: MONARCH-928
    T. Mok, L. Paz-Ares, M. Reck · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  83. Abstract 12472026-09-02 · 21:00 CT · Hall B1
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-525 study)
    H. Rugo, P. Schmid, T. Mok · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  84. Abstract 16972026-09-04 · 19:45 CT · E450
    Long-term follow-up of Ibrance adjuvant for HR+ breast cancer: PALOMA-680
    L. Paz-Ares, H. Borghaei · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  85. Abstract 12682026-09-02 · 20:15 CT · Arie Crown Theater
    Long-term follow-up of Ibrance maintenance for HR+ breast cancer: PALOMA-212
    L. Paz-Ares, T. Mok · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  86. Abstract 15112026-09-02 · 15:15 CT · Hall B1
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-916 study)
    L. Paz-Ares, F. Andre, S. Antonia · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  87. Abstract 14392026-09-04 · 13:30 CT · S100A
    MONALEESA-74: Kisqali (ribociclib) 3L+ in HR+ breast cancer
    S. Modi, C. Saura, J. Brahmer, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  88. Abstract 17412026-09-02 · 20:00 CT · E450
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-794
    R. Herbst, F. Andre, H. Borghaei, et al. · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  89. Abstract 10812026-09-01 · 21:30 CT · Hall B1
    MONALEESA-412: Kisqali (ribociclib) maintenance in HR+ breast cancer
    L. Paz-Ares, G. Curigliano, J. Brahmer, et al. · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  90. Abstract 10612026-09-02 · 19:30 CT · E450
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-541 study)
    T. Mok, H. Rugo, R. Herbst · Princess Margaret Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  91. Abstract 17092026-09-01 · 14:15 CT · S406
    Long-term follow-up of Kisqali neoadjuvant for HR+ breast cancer: MONALEESA-281
    C. Robert, F. Andre · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  92. Abstract 10112026-09-03 · 18:00 CT · S406
    MONARCH-853: Verzenio (abemaciclib) 3L+ in HR+ breast cancer
    N. Rizvi, P. Schmid, S. Tolaney · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  93. Abstract 11972026-09-04 · 18:30 CT · S406
    Long-term follow-up of Ibrance adjuvant for HR+ breast cancer: PALOMA-608
    L. Paz-Ares, F. Andre · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  94. Abstract 12262026-09-04 · 15:45 CT · E450
    OlympiA-699: Lynparza (olaparib) 3L+ in HR+ breast cancer
    T. Mok, L. Paz-Ares · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  95. Abstract 19322026-09-04 · 20:30 CT · E450
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-135
    H. Rugo, H. Borghaei · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  96. Abstract 10502026-09-04 · 20:45 CT · Arie Crown Theater
    MONARCH-645: Verzenio (abemaciclib) maintenance in HR+ breast cancer
    J. Brahmer, S. Modi, S. Antonia, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  97. Abstract 14072026-09-04 · 19:45 CT · S100A
    Long-term follow-up of Ibrance maintenance for HR+ breast cancer: PALOMA-231
    N. Rizvi, G. Curigliano, H. Rugo, et al. · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  98. Abstract 13262026-09-03 · 18:30 CT · Hall B1
    Real-world effectiveness of Lynparza vs standard of care in HR+ breast cancer
    A. Spira, C. Robert, C. Saura, et al. · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  99. Abstract 11362026-09-03 · 20:15 CT · E450
    OlympiA-546: Lynparza (olaparib) adjuvant in HR+ breast cancer
    N. Rizvi, S. Antonia · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  100. Abstract 15882026-09-04 · 15:15 CT · E450
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-820 study)
    M.C. Garassino, F. Andre, N. Rizvi · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  101. Abstract 13112026-09-01 · 14:30 CT · Arie Crown Theater
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-960
    H. Rugo, E. Winer, C. Robert, et al. · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  102. Abstract 16122026-09-02 · 19:00 CT · E450
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-864 study)
    N. Rizvi, T. Mok, J. Cortes, et al. · Princess Margaret Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  103. Abstract 14192026-09-01 · 21:45 CT · S100A
    Long-term follow-up of Ibrance neoadjuvant for HR+ breast cancer: PALOMA-619
    H. Rugo, R. Herbst, G. Curigliano, et al. · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  104. Abstract 15752026-09-03 · 13:15 CT · S406
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-890 study)
    N. Rizvi, C. Robert, R. Herbst · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  105. Abstract 18462026-09-05 · 20:00 CT · E450
    MONALEESA-186: Kisqali (ribociclib) neoadjuvant in HR+ breast cancer
    C. Robert, N. Rizvi · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  106. Abstract 14552026-09-04 · 18:30 CT · S406
    Long-term follow-up of Lynparza 1L for HR+ breast cancer: OlympiA-830
    L. Paz-Ares, P. Schmid, T. Mok, et al. · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  107. Abstract 18412026-09-04 · 15:30 CT · S406
    MONALEESA-212: Kisqali (ribociclib) adjuvant in HR+ breast cancer
    S. Tolaney, P. Schmid · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  108. Abstract 18122026-09-04 · 16:30 CT · S100A
    Long-term follow-up of Keytruda neoadjuvant for TNBC: KEYNOTE-383
    S. Antonia, H. Rugo, H. Borghaei, et al. · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  109. Abstract 18932026-09-05 · 13:30 CT · E450
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-309
    M. Reck, R. Herbst, S. Tolaney · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  110. Abstract 12652026-09-03 · 16:00 CT · E450
    PALOMA-340: Ibrance (palbociclib) 1L in HR+ breast cancer
    G. Curigliano, N. Rizvi · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  111. Abstract 18292026-09-01 · 18:15 CT · Arie Crown Theater
    MONARCH-499: Verzenio (abemaciclib) 1L in HR+ breast cancer
    M. Reck, M.C. Garassino · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  112. Abstract 18402026-09-01 · 19:00 CT · S100A
    Long-term follow-up of Ibrance 3L+ for HR+ breast cancer: PALOMA-442
    T. Mok, C. Saura, M. Reck, et al. · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  113. Abstract 10542026-09-01 · 16:15 CT · Arie Crown Theater
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-619
    M. Krop, S. Peters, J. Cortes, et al. · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  114. Abstract 15102026-09-04 · 13:45 CT · Hall B1
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-176
    S. Modi, N. Rizvi, F. Andre, et al. · Stanford Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  115. Abstract 12932026-09-01 · 14:15 CT · E450
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-177
    A. Spira, P. Schmid, S. Peters · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  116. Abstract 19832026-09-01 · 13:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-399 study)
    F. Andre, M. Krop, J. Brahmer, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  117. Abstract 10102026-09-03 · 14:00 CT · S406
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-898
    S. Antonia, H. Rugo, J. Brahmer, et al. · Stanford Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  118. Abstract 15262026-09-05 · 13:15 CT · Hall B1
    KEYNOTE-523: Keytruda (pembrolizumab) adjuvant in TNBC
    T. Mok, M.C. Garassino · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  119. Abstract 17042026-09-01 · 14:30 CT · E450
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-211
    S. Peters, A. Spira, F. Andre, et al. · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  120. Abstract 10012026-09-04 · 19:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in TNBC (the KEYNOTE-224 study)
    H. Rugo, P. Schmid · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  121. Abstract 12332026-09-03 · 14:30 CT · E450
    Long-term follow-up of Kisqali 1L for HR+ breast cancer: MONALEESA-615
    M.C. Garassino, M. Reck, C. Saura · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  122. Abstract 18692026-09-02 · 21:30 CT · S100A
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-856
    S. Tolaney, F. Andre · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  123. Abstract 19002026-09-04 · 21:45 CT · S406
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-658 study)
    T. Mok, J. Cortes, L. Paz-Ares, et al. · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  124. Abstract 10302026-09-03 · 15:30 CT · Hall B1
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-263 study)
    M. Krop, S. Peters, S. Tolaney, et al. · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  125. Abstract 10922026-09-02 · 15:15 CT · Hall B1
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-462 study)
    F. Andre, M. Krop, S. Tolaney · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  126. Abstract 13942026-09-04 · 21:30 CT · S100A
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-800 study)
    L. Paz-Ares, J. Brahmer, N. Rizvi · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  127. Abstract 13662026-09-01 · 14:30 CT · S406
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-819
    S. Tolaney, T. Mok, A. Spira · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  128. Abstract 14452026-09-04 · 21:15 CT · Hall B1
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-331
    S. Antonia, C. Robert, N. Rizvi · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  129. Abstract 10392026-09-03 · 19:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-241 study)
    T. Mok, S. Peters, E. Winer, et al. · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  130. Abstract 17892026-09-02 · 13:45 CT · E450
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-512
    C. Robert, G. Curigliano, S. Tolaney, et al. · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  131. Abstract 14362026-09-02 · 21:30 CT · Hall B1
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-382 study)
    C. Saura, M. Reck · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  132. Abstract 14932026-09-01 · 19:15 CT · Hall B1
    Long-term follow-up of Ibrance maintenance for HR+ breast cancer: PALOMA-459
    E. Winer, T. Mok, N. Rizvi, et al. · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  133. Abstract 19832026-09-04 · 21:30 CT · E450
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-838
    M. Reck, F. Andre, R. Herbst, et al. · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  134. Abstract 10222026-09-05 · 13:00 CT · Hall B1
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-709 study)
    A. Spira, S. Modi, L. Paz-Ares · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  135. Abstract 10642026-09-01 · 21:45 CT · E450
    Long-term follow-up of Trodelvy 3L+ for TNBC: ASCENT-681
    M.C. Garassino, S. Modi, E. Winer · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  136. Abstract 18412026-09-03 · 18:30 CT · Arie Crown Theater
    Long-term follow-up of Trodelvy 1L for TNBC: ASCENT-276
    R. Herbst, H. Borghaei, F. Andre, et al. · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  137. Abstract 16482026-09-01 · 14:30 CT · E450
    Long-term follow-up of Ibrance 3L+ for HR+ breast cancer: PALOMA-10
    N. Rizvi, M.C. Garassino, S. Peters, et al. · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  138. Abstract 12712026-09-05 · 14:15 CT · Arie Crown Theater
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-378
    C. Robert, G. Curigliano, C. Saura · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  139. Abstract 16852026-09-04 · 19:30 CT · Arie Crown Theater
    MONALEESA-101: Kisqali (ribociclib) maintenance in HR+ breast cancer
    M. Krop, S. Tolaney · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  140. Abstract 15402026-09-04 · 20:00 CT · E450
    Long-term follow-up of Verzenio neoadjuvant for HR+ breast cancer: MONARCH-260
    T. Mok, H. Borghaei, H. Rugo, et al. · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  141. Abstract 12242026-09-05 · 15:15 CT · S100A
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-806
    S. Antonia, A. Spira · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  142. Abstract 14112026-09-04 · 13:00 CT · S406
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-584 study)
    R. Herbst, S. Modi, M. Krop, et al. · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  143. Abstract 11982026-09-04 · 16:45 CT · Hall B1
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-680 study)
    G. Curigliano, L. Paz-Ares, T. Mok · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  144. Abstract 18832026-09-01 · 13:30 CT · Hall B1
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-869 study)
    H. Borghaei, S. Peters, R. Herbst · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  145. Abstract 19882026-09-02 · 14:15 CT · Hall B1
    ASCENT-546: Trodelvy (sacituzumab govitecan) 3L+ in TNBC
    S. Antonia, H. Rugo · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  146. Abstract 17432026-09-05 · 21:00 CT · Hall B1
    Biomarker subgroup analysis of Keytruda in TNBC (the KEYNOTE-16 study)
    S. Modi, N. Rizvi, F. Andre, et al. · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  147. Abstract 13902026-09-02 · 16:15 CT · E450
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-888 study)
    R. Herbst, F. Andre · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  148. Abstract 15862026-09-02 · 15:45 CT · S100A
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-182 study)
    M. Reck, S. Peters, M.C. Garassino, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  149. Abstract 16642026-09-01 · 14:00 CT · Arie Crown Theater
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-438
    J. Cortes, F. Andre, J. Brahmer, et al. · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  150. Abstract 18222026-09-03 · 14:30 CT · Arie Crown Theater
    Long-term follow-up of Lynparza 2L for HR+ breast cancer: OlympiA-554
    J. Cortes, S. Modi, F. Andre · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  151. Abstract 19912026-09-03 · 14:00 CT · Hall B1
    PALOMA-624: Ibrance (palbociclib) 1L in HR+ breast cancer
    H. Rugo, S. Peters, S. Antonia, et al. · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  152. Abstract 12122026-09-02 · 14:00 CT · S406
    MONARCH-282: Verzenio (abemaciclib) adjuvant in HR+ breast cancer
    T. Mok, N. Rizvi, H. Rugo, et al. · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  153. Abstract 10922026-09-02 · 19:30 CT · E450
    Long-term follow-up of Enhertu neoadjuvant for HR+ breast cancer: DESTINY-Breast-302
    L. Paz-Ares, C. Saura · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  154. Abstract 14142026-09-03 · 18:15 CT · S406
    Long-term follow-up of Ibrance neoadjuvant for HR+ breast cancer: PALOMA-925
    C. Saura, C. Robert, F. Andre, et al. · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  155. Abstract 17292026-09-02 · 16:45 CT · Arie Crown Theater
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-623
    S. Antonia, M. Krop, N. Rizvi, et al. · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  156. Abstract 12182026-09-02 · 13:30 CT · Arie Crown Theater
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-267
    S. Antonia, P. Schmid, J. Cortes · Stanford Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  157. Abstract 17722026-09-04 · 19:45 CT · S406
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-235 study)
    L. Paz-Ares, E. Winer · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  158. Abstract 18602026-09-05 · 15:30 CT · E450
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-6
    E. Winer, H. Rugo · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  159. Abstract 12072026-09-05 · 20:00 CT · E450
    PALOMA-210: Ibrance (palbociclib) maintenance in HR+ breast cancer
    S. Peters, E. Winer, N. Rizvi, et al. · Stanford Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  160. Abstract 11122026-09-04 · 19:15 CT · E450
    PALOMA-985: Ibrance (palbociclib) maintenance in HR+ breast cancer
    C. Saura, M. Krop · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  161. Abstract 13032026-09-04 · 13:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-985 study)
    E. Winer, H. Borghaei, P. Schmid, et al. · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  162. Abstract 17432026-09-03 · 19:00 CT · Arie Crown Theater
    MONALEESA-643: Kisqali (ribociclib) 2L in HR+ breast cancer
    S. Antonia, H. Borghaei, N. Rizvi, et al. · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  163. Abstract 13632026-09-03 · 15:00 CT · S100A
    DESTINY-Breast-906: Enhertu (trastuzumab deruxtecan) neoadjuvant in HR+ breast cancer
    J. Brahmer, H. Borghaei, F. Andre, et al. · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  164. Abstract 19432026-09-02 · 20:00 CT · Hall B1
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-181
    L. Paz-Ares, M.C. Garassino, J. Cortes · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  165. Abstract 12012026-09-03 · 16:30 CT · Hall B1
    Long-term follow-up of Ibrance 3L+ for HR+ breast cancer: PALOMA-931
    R. Herbst, F. Andre, H. Rugo · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  166. Abstract 11562026-09-03 · 16:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-382 study)
    P. Schmid, M. Reck · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  167. Abstract 11542026-09-05 · 18:45 CT · Arie Crown Theater
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-742
    M.C. Garassino, A. Spira, S. Antonia · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  168. Abstract 16732026-09-04 · 15:15 CT · E450
    DESTINY-Breast-500: Enhertu (trastuzumab deruxtecan) adjuvant in HR+ breast cancer
    T. Mok, N. Rizvi, J. Brahmer · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  169. Abstract 10572026-09-03 · 21:45 CT · Hall B1
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-732
    S. Tolaney, P. Schmid, R. Herbst · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  170. Abstract 16172026-09-03 · 19:45 CT · S406
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-46
    N. Rizvi, J. Brahmer · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  171. Abstract 14402026-09-03 · 21:30 CT · E450
    Biomarker subgroup analysis of Keytruda in TNBC (the KEYNOTE-887 study)
    M. Reck, S. Antonia, S. Tolaney, et al. · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  172. Abstract 15662026-09-03 · 21:45 CT · S100A
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-458 study)
    A. Spira, C. Robert, S. Peters · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  173. Abstract 19232026-09-01 · 19:45 CT · Arie Crown Theater
    Long-term follow-up of Lynparza 2L for HR+ breast cancer: OlympiA-324
    M. Krop, G. Curigliano · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  174. Abstract 14102026-09-01 · 19:45 CT · Arie Crown Theater
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-903
    M. Reck, C. Saura, H. Borghaei, et al. · Stanford Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  175. Abstract 13582026-09-02 · 18:30 CT · Arie Crown Theater
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-225
    F. Andre, R. Herbst · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  176. Abstract 15752026-09-01 · 20:15 CT · S406
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-796 study)
    C. Robert, J. Cortes, R. Herbst, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  177. Abstract 14812026-09-01 · 13:45 CT · Hall B1
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-243 study)
    J. Cortes, C. Robert, S. Tolaney, et al. · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  178. Abstract 11522026-09-03 · 21:15 CT · Hall B1
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-398
    N. Rizvi, P. Schmid, C. Robert, et al. · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  179. Abstract 13422026-09-01 · 15:00 CT · E450
    Long-term follow-up of Trodelvy 3L+ for TNBC: ASCENT-457
    A. Spira, S. Peters · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  180. Abstract 14102026-09-04 · 16:00 CT · S406
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-9 study)
    J. Brahmer, S. Antonia, L. Paz-Ares, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  181. Abstract 12192026-09-05 · 16:00 CT · S406
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-57
    R. Herbst, N. Rizvi, S. Antonia, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  182. Abstract 16182026-09-04 · 21:15 CT · E450
    Long-term follow-up of Kisqali maintenance for HR+ breast cancer: MONALEESA-487
    P. Schmid, R. Herbst, A. Spira · Princess Margaret Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  183. Abstract 14292026-09-02 · 14:45 CT · Hall B1
    Long-term follow-up of Verzenio neoadjuvant for HR+ breast cancer: MONARCH-418
    J. Cortes, F. Andre, A. Spira, et al. · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  184. Abstract 13632026-09-05 · 14:30 CT · Hall B1
    Long-term follow-up of Trodelvy adjuvant for TNBC: ASCENT-741
    M. Krop, H. Rugo, S. Antonia, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  185. Abstract 10392026-09-04 · 14:00 CT · S406
    IMpower-927: Tecentriq (atezolizumab) adjuvant in TNBC
    J. Cortes, S. Modi, M. Krop, et al. · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  186. Abstract 13522026-09-05 · 19:30 CT · S406
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-779
    M. Reck, M.C. Garassino, G. Curigliano · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  187. Abstract 10862026-09-03 · 20:15 CT · S406
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-342 study)
    N. Rizvi, J. Brahmer · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  188. Abstract 10702026-09-03 · 18:15 CT · Arie Crown Theater
    Long-term follow-up of Verzenio 3L+ for HR+ breast cancer: MONARCH-499
    S. Modi, C. Robert, M. Krop, et al. · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  189. Abstract 14102026-09-01 · 18:45 CT · S100A
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-606 study)
    S. Modi, C. Saura, J. Brahmer · Stanford Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  190. Abstract 10442026-09-03 · 16:30 CT · E450
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-144 study)
    H. Rugo, M. Krop, L. Paz-Ares, et al. · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  191. Abstract 16922026-09-02 · 18:30 CT · Hall B1
    Biomarker subgroup analysis of Keytruda in TNBC (the KEYNOTE-22 study)
    C. Saura, T. Mok · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  192. Abstract 19432026-09-04 · 15:00 CT · Hall B1
    MONALEESA-341: Kisqali (ribociclib) adjuvant in HR+ breast cancer
    S. Antonia, T. Mok, R. Herbst, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  193. Abstract 16602026-09-02 · 16:15 CT · Hall B1
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-10 study)
    N. Rizvi, S. Peters, S. Modi · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  194. Abstract 17102026-09-04 · 16:30 CT · S100A
    Long-term follow-up of Trodelvy maintenance for TNBC: ASCENT-529
    H. Borghaei, M. Krop · Princess Margaret Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  195. Abstract 10242026-09-01 · 14:45 CT · Hall B1
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-696
    H. Rugo, H. Borghaei, L. Paz-Ares · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  196. Abstract 18082026-09-02 · 19:15 CT · S406
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-81
    E. Winer, G. Curigliano, L. Paz-Ares, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  197. Abstract 12662026-09-02 · 16:45 CT · S100A
    Long-term follow-up of Kisqali adjuvant for HR+ breast cancer: MONALEESA-690
    P. Schmid, M. Krop, L. Paz-Ares, et al. · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  198. Abstract 15752026-09-02 · 21:00 CT · Hall B1
    Long-term follow-up of Keytruda 2L for TNBC: KEYNOTE-321
    P. Schmid, J. Cortes, C. Saura, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  199. Abstract 15982026-09-03 · 19:45 CT · E450
    PALOMA-74: Ibrance (palbociclib) maintenance in HR+ breast cancer
    S. Peters, S. Tolaney, L. Paz-Ares, et al. · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  200. Abstract 12752026-09-05 · 19:30 CT · S100A
    Biomarker subgroup analysis of Keytruda in TNBC (the KEYNOTE-729 study)
    G. Curigliano, A. Spira, C. Robert, et al. · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.